NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready.
The therapy is advancing toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers. NV-387 is a broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, and has shown effectiveness in animal models for monkeypox, smallpox, and measles.
“We are pleased to have completed the manufacturing of NV-387 Oral Gummies, a key milestone as we prepare for patient dosing,” said Anil R. Diwan, President and Executive Chairman. “We look forward to presenting our progress at the NIBA conference and discussing the potential of our broad-spectrum antiviral platform with the investment community.”
NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is currently focused on advancing NV-387 into Phase II human clinical trials. The completion of the oral gummies drug product marks a significant step in the preparation for the next stage of clinical development.
For more information on NanoViricides and its pipeline, visit the company’s newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/AILOVA.
The NIBA Investment Conference provides a platform for companies to present their investment thesis to a targeted audience of investors and analysts. NanoViricides’ presentation is expected to highlight the company’s progress and the potential of its novel antiviral approach.
NanoViricides is a clinical stage company that creates special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a unique broad-spectrum antiviral with potential applications across multiple viral diseases. The company’s other advanced drug candidate is NV-HHV-1 for the treatment of all Herpesvirus infections.
